Document Detail


Exposure to attention deficit hyperactivity disorder medications during pregnancy.
MedLine Citation:
PMID:  17872810     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
QUESTION: An 18-year-old patient of mine, currently under treatment for attention deficit hyperactivity disorder (ADHD) with methylphenidate, just found out that she is pregnant. What are the risks for the baby when the mother uses ADHD medications during pregnancy?
ANSWER: Available evidence for amphetamines suggests no increased risk of malformations with use of therapeutic doses, and inadvertent exposure during pregnancy is unlikely to be harmful. Human data for methylphenidate and atomoxetine treatment in pregnancy are very limited. Documented cases do not suggest teratogenicity, but we cannot rule out this risk with the information available.
Authors:
Caitlin Humphreys; Facundo Garcia-Bournissen; Shinya Ito; Gideon Koren
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Canadian family physician Médecin de famille canadien     Volume:  53     ISSN:  1715-5258     ISO Abbreviation:  Can Fam Physician     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-09-17     Completed Date:  2007-10-18     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  0120300     Medline TA:  Can Fam Physician     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1153-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced / prevention & control*
Attention Deficit Disorder with Hyperactivity / diagnosis,  drug therapy*
Central Nervous System Stimulants / adverse effects*,  therapeutic use
Congenital Abnormalities
Decision Making
Drug Toxicity
Female
Humans
Infant, Newborn
Methylphenidate / adverse effects,  therapeutic use
Pregnancy
Pregnancy Complications / drug therapy*
Propylamines / adverse effects,  therapeutic use
Risk Assessment
Chemical
Reg. No./Substance:
0/Central Nervous System Stimulants; 0/Propylamines; 113-45-1/Methylphenidate; ASW034S0B8/atomoxetine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Room for improvement: patients' experiences of primary care in Quebec before major reforms.
Next Document:  Carpal tunnel syndrome and vitamin B6.